Skip to main content

Estradiol increases ER-negative breast cancer metastasis in an experimental model

Clinical & Experimental Metastasis volume 30, pages 711–721 (2013)Cite this article

Abstract

Breast cancer (BC) is the most common cancer affecting women in the United States and metastatic breast cancer is the leading cause of death. The role estradiol plays in ER-positive BC is well-documented, but the way it contributes to ER-negative BC remains unclear. In the present study, we utilized an experimental model of BC metastasis into lung by injecting ER-negative murine 4T1 cells into mice via the lateral tail vein. A 56 % metastasis occurrence rate following the injection of 5 × 103 cells was observed, thus this cell number was selected to study the potential stimulatory effect of estradiol on ER-negative BC metastasis. Female ovariectomized mice were randomized into estradiol and control groups with 16 mice per group, and estradiol pellets were implanted subcutaneously in the estradiol group. Results demonstrated that estradiol accelerated BC metastasis as indicated by bioluminescent imaging. In addition, estradiol enhanced metastatic tumor colony formation and increased the size of tumor nodules in the lungs, which were due, in part, to the increase in proliferative cells in the metastatic tumors. In vitro, estradiol increased the motility and invasion of 4T1 cells, and the stimulatory effect on cell motility was not blocked by ICI 182, 780, confirming that ER was not involved in the process. Results from the present study suggest that estradiol plays a role in ER-negative BC metastasis in whole animals.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Jemal A et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100(23):1672–1694

    PubMed  Article  Google Scholar 

  2. Hagemeister FB Jr et al (1980) Causes of death in breast cancer: a clinicopathologic study. Cancer 46(1):162–167

    PubMed  Article  Google Scholar 

  3. Jemal A et al (2003) Cancer statistics, 2003. CA Cancer J Clin 53(1):5–26

    PubMed  Article  Google Scholar 

  4. Pavese JM, Farmer RL, Bergan RC (2010) Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 29(3):465–482

    PubMed  Article  CAS  Google Scholar 

  5. Rosen PR et al (1989) A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7(3):355–366

    PubMed  CAS  Google Scholar 

  6. Lee YT (1985) Patterns of metastasis and natural courses of breast carcinoma. Cancer Metastasis Rev 4(2):153–172

    PubMed  Article  CAS  Google Scholar 

  7. Horwitz KB (2008) The year in basic science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Mol Endocrinol 22(12):2743–2750

    PubMed  Article  CAS  Google Scholar 

  8. Ma H et al (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8(4):R43

    PubMed  Article  Google Scholar 

  9. Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276–285

    PubMed  Article  CAS  Google Scholar 

  10. Kaaks R et al (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12(4):1071–1082

    PubMed  Article  CAS  Google Scholar 

  11. Diaz LK, Sneige N (2005) Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 12(1):10–19

    PubMed  Article  CAS  Google Scholar 

  12. Skliris GP et al (2008) Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 109(1–2):1–10

    PubMed  Article  CAS  Google Scholar 

  13. Fox EM, Davis RJ, Shupnik MA (2008) ERbeta in breast cancer–onlooker, passive player, or active protector? Steroids 73(11):1039–1051

    PubMed  Article  CAS  Google Scholar 

  14. Omoto Y et al (2003) Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22(32):5011–5020

    PubMed  Article  CAS  Google Scholar 

  15. Buteau-Lozano H et al (2002) Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res 62(17):4977–4984

    PubMed  CAS  Google Scholar 

  16. Chang EC et al (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147(10):4831–4842

    PubMed  Article  CAS  Google Scholar 

  17. Matthews J et al (2006) Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 20(3):534–543

    PubMed  Article  CAS  Google Scholar 

  18. Roger P et al (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61(6):2537–2541

    PubMed  CAS  Google Scholar 

  19. Leygue E et al (1998) Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 58(15):3197–3201

    PubMed  CAS  Google Scholar 

  20. Jarvinen TA et al (2000) Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 156(1):29–35

    PubMed  Article  CAS  Google Scholar 

  21. Fuqua SA et al (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63(10):2434–2439

    PubMed  CAS  Google Scholar 

  22. O’Neill PA et al (2004) Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91(9):1694–1702

    PubMed  Google Scholar 

  23. Platet N et al (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51(1):55–67

    PubMed  Article  Google Scholar 

  24. Neven P et al (2002) Endocrine treatment and prevention of breast and gynaecological cancers. Eur J Cancer 38(Suppl 6):S1–S11

    PubMed  Article  CAS  Google Scholar 

  25. Vergote I et al (2000) The oestrogen receptor and its selective modulators in gynaecological and breast cancer. Eur J Cancer 36(Suppl 4):S1–S9

    PubMed  Article  CAS  Google Scholar 

  26. Hartman J, Strom A, Gustafsson JA (2009) Estrogen receptor beta in breast cancer–diagnostic and therapeutic implications. Steroids 74(8):635–641

    PubMed  Article  CAS  Google Scholar 

  27. Warner M, Gustafsson JA (2010) The role of estrogen receptor beta (ERbeta) in malignant diseases–a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 396(1):63–66

    PubMed  Article  CAS  Google Scholar 

  28. Yue W et al (2010) Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms. Int J Cancer 127(8):1748–1757

    PubMed  Article  CAS  Google Scholar 

  29. Acconcia F, Kumar R (2006) Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett 238(1):1–14

    PubMed  Article  CAS  Google Scholar 

  30. Bjornstrom L, Sjoberg M (2005) Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19(4):833–842

    PubMed  Article  Google Scholar 

  31. Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8784):1–15

    Google Scholar 

  32. Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8785):71–85

    Google Scholar 

  33. Gupta PB et al (2007) Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 67(5):2062–2071

    PubMed  Article  CAS  Google Scholar 

  34. Banka CL et al (2006) Estrogen induces lung metastasis through a host compartment-specific response. Cancer Res 66(7):3667–3672

    PubMed  Article  CAS  Google Scholar 

  35. Reeves PG, Nielsen FH, Fahey GC Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123(11):1939–1951

    PubMed  CAS  Google Scholar 

  36. Miller FR (1983) Tumor subpopulation interactions in metastasis. Invasion Metastasis 3(4):234–242

    PubMed  CAS  Google Scholar 

  37. Miller FR, Miller BE, Heppner GH (1983) Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3(1):22–31

    PubMed  CAS  Google Scholar 

  38. Hong X et al (2009) EBAG9 inducing hyporesponsiveness of T cells promotes tumor growth and metastasis in 4T1 murine mammary carcinoma. Cancer Sci 100(5):961–969

    PubMed  Article  CAS  Google Scholar 

  39. Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6):1399–1405

    PubMed  CAS  Google Scholar 

  40. Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58(7):1486–1493

    PubMed  CAS  Google Scholar 

  41. Pulaski, B.A. and S. Ostrand-Rosenberg, Mouse 4T1 breast tumor model. Curr Protoc Immunol, 2001. Chapter 20: p. Unit-Uni2

  42. Adams LS et al (2010) Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway. Cancer Res 70(9):3594–3605

    PubMed  Article  CAS  Google Scholar 

  43. Valster A et al (2005) Cell migration and invasion assays. Methods 37(2):208–215

    PubMed  Article  CAS  Google Scholar 

  44. Ju YH et al (2001) Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 131(11):2957–2962

    PubMed  CAS  Google Scholar 

  45. Ju YH et al (2006) Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis 27(6):1292–1299

    PubMed  Article  CAS  Google Scholar 

  46. Hiraga T et al (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10(13):4559–4567

    PubMed  Article  CAS  Google Scholar 

  47. Muller A et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56

    PubMed  Article  CAS  Google Scholar 

  48. Ju YH et al (2006) Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis 27(4):856–863

    PubMed  Article  CAS  Google Scholar 

  49. Pike MC et al (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):17–35

    PubMed  CAS  Google Scholar 

  50. Gottardis MM, Robinson SP, Jordan VC (1988) Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30(1–6):311–314

    PubMed  Article  CAS  Google Scholar 

  51. Alliende ME (2002) Mean versus individual hormonal profiles in the menstrual cycle. Fertil Steril 78(1):90–95

    PubMed  Article  Google Scholar 

  52. Kaaks R et al (2005) Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97(10):755–765

    PubMed  Article  CAS  Google Scholar 

  53. Bockhorn M, Jain RK, Munn LL (2007) Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol 8(5):444–448

    PubMed  Article  CAS  Google Scholar 

  54. Nogawa M et al (2005) Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett 217(2):243–253

    PubMed  Article  CAS  Google Scholar 

  55. Uneda S et al (2009) Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 125(6):1446–1453

    PubMed  Article  CAS  Google Scholar 

  56. Oviedo PJ et al (2011) Estradiol induces endothelial cell migration and proliferation through estrogen receptor-enhanced RhoA/ROCK pathway. Mol Cell Endocrinol 335(2):96–103

    PubMed  Article  CAS  Google Scholar 

  57. Acconcia F, Barnes CJ, Kumar R (2006) Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology 147(3):1203–1212

    PubMed  Article  CAS  Google Scholar 

  58. Sanchez AM et al (2010) Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 24(11):2114–2125

    PubMed  Article  CAS  Google Scholar 

  59. Kedrin D et al (2007) Cell motility and cytoskeletal regulation in invasion and metastasis. J Mammary Gland Biol Neoplasia 12(2–3):143–152

    PubMed  Article  Google Scholar 

  60. Giretti MS et al (2008) Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS ONE 3(5):e2238

    PubMed  Article  Google Scholar 

  61. Zheng S et al (2011) 17beta-Estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin. PLoS ONE 6(7):e22439

    PubMed  Article  CAS  Google Scholar 

  62. Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89(17):1260–1270

    PubMed  Article  CAS  Google Scholar 

  63. Nilsson UW, Garvin S, Dabrosin C (2007) MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat 102(3):253–261

    PubMed  Article  CAS  Google Scholar 

  64. Migliaccio A et al (1996) Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15(6):1292–1300

    PubMed  CAS  Google Scholar 

  65. Zhang Z et al (2004) The role of adapter protein Shc in estrogen non-genomic action. Steroids 69(8–9):523–529

    PubMed  Article  CAS  Google Scholar 

  66. Song RX et al (2004) The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A 101(7):2076–2081

    PubMed  Article  CAS  Google Scholar 

  67. Yang Z, Barnes CJ, Kumar R (2004) Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 10(11):3621–3628

    PubMed  Article  CAS  Google Scholar 

  68. Restall C et al (2009) A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth. Int J Cancer 125(2):483–487

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgement

This study was supported by the National Cancer Institute [CA77355 to W.G.H.]; the National Institute on Aging, the National Institute for Complementary and Alternative Medicine and the Office of Dietary Supplements, the Women’s Health Initiative [P01 AG024387 to W.G.H. and Y.H.J.]; and the National Institute for Complementary and Alternative Medicine, the Office of Dietary Supplements and the National Cancer Institute [P50AT006268 to W.G.H.]. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NICAM, ODS, NCI or the National Institutes of Health.

Conflict of interests

None declared.

Author information

Authors and Affiliations

  1. Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA

    Xujuan Yang, Aashvini Belosay, Mengyuan Du & William G. Helferich

  2. Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA

    Timothy M. Fan

  3. Skeletal Biology Laboratory, School of Biological and Population Health Sciences, Oregon State University, Corvallis, OR, 97331, USA

    Russell T. Turner & Urszula T. Iwaniec

Authors
  1. Xujuan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aashvini Belosay
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mengyuan Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Timothy M. Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Russell T. Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Urszula T. Iwaniec
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. William G. Helferich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William G. Helferich.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yang, X., Belosay, A., Du, M. et al. Estradiol increases ER-negative breast cancer metastasis in an experimental model. Clin Exp Metastasis 30, 711–721 (2013). https://doi.org/10.1007/s10585-012-9559-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-012-9559-0

Keywords

  • ER-negative breast cancer
  • Metastasis
  • Estradiol
  • 4T1 cells